Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Disruption of VEGF-A Expression in Human Retinal Pigment Epithelial Cells Using CRISPR-Cas9 Endonuclease.

Investigative ophthalmology & visual science - 1 Oct 2016

Yiu Glenn, Tieu Eric, Nguyen Anthony T, Wong Brittany, Smit-McBride Zeljka

Abstract excerpt

PURPOSE: To employ type II clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 endonuclease to suppress ocular angiogenesis by genomic disruption of VEGF-A in human RPE cells. METHODS: CRISPR sequences targeting exon 1 of human VEGF-A were computationally identified based on predicted Cas9 on- and off-target probabilities. Single guide RNA (gRNA) cassettes with these target sequences were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Choroidal Neovascularization
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Associated Protein 9

Share to Endonucleases

Share to Enzyme-Linked Immunosorbent Assay

Share to Retinal Pigment Epithelium

Share to RNA, Guide, CRISPR-Cas Systems

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 27768202
DOI: 10.1167/iovs.16-20296
PMCID: PMC5072539

Genes

RPE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Disruption of VEGF-A Expression in Human Retinal Pigment Epithelial Cells Using CRISPR-Cas9 Endonuclease.PMID 27768202Read ↗

CRISPR Technology for Ocular AngiogenesisSemantic proximity Read ↗

Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal NeovascularizationSemantic proximity Read ↗

Genome editing abrogates angiogenesis in vivoSemantic proximity Read ↗

CRISPR/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularizationSemantic proximity Read ↗

Comparison of CRISPR/Cas endonucleases for <i>in vivo</i> retinal gene editingSemantic proximity Read ↗

Genome Editing VEGFA Prevents Corneal Neovascularization In VivoSemantic proximity Read ↗

The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.Semantic proximity Read ↗

The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells.Semantic proximity Read ↗

Efficacy and dynamics of self-targeting CRISPR/Cas constructs for gene editing in the retinaSemantic proximity Read ↗

Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyesSemantic proximity Read ↗

Targeting vascular endothelial growth factor using retinal gene therapySemantic proximity Read ↗

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.